Evidence tracker Chronic pain Knee

Genicular nerve radiofrequency ablation

For chronic knee pain from osteoarthritis, including after total knee arthroplasty. Conventional, cooled and pulsed techniques compared against sham, intra-articular injections and usual care.

Indexed papers
14
matching, retractions excluded
Randomized trials
1
plus 0 meta-analyses
With AI summary
14
others show original abstract
Registered, not results
18
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 14 of 14

Recent evidence · past year

  1. Other Pain ManagPublished 3 Nov 2026 Takemoto N et al.
    Short-term clinical and imaging outcomes after ultrasound-guided cooled radiofrequency ablation for advanced knee osteoarthritis: a retrospective cohort study.
    AI summary of the abstract, unverified
    • Retrospective single-arm cohort of 31 patients (35 knees), mean age 73.6 years, with Kellgren-Lawrence grade 3 or 4 in 91%, treated at a single setting.
    • Patients received ultrasound-guided cooled radiofrequency ablation for knee osteoarthritis, with outcomes compared from baseline to 3 months; no control group was included.
    • Walking VAS pain fell by 24.0 points and KOOS Pain rose by 12.8 points (p < 0.001), with 42.9% of knees reaching at least a 50% walking-pain reduction.
    • The authors concluded that pain and function improved at 3 months without group-level worsening of KL grade, alignment, or bone marrow lesions, and that no serious procedure-related adverse events were recorded.
    Original abstract (PubMed)

    OBJECTIVE: To evaluate short-term clinical and imaging outcomes after ultrasound-guided cooled radiofrequency ablation (CRFA) in patients predominantly with advanced knee osteoarthritis (KOA). METHODS: This retrospective cohort analysis included prospectively recorded data from 31 patients (35 knees; age, 73.6 ± 8.8 years; Kellgren-Lawrence [KL] grade 3 or 4 in 91%). Outcomes at baseline and 3 months included visual analog scale (VAS) pain, Knee Injury and Osteoarthritis Outcome Score (KOOS), KL grade, mechanical axis percentage, and MRI Osteoarthritis Knee Score assessments of bone marrow lesions (BMLs), Hoffa-synovitis, and effusion-synovitis. Sensitivity analysis retained the first-treated knee in bilateral cases. RESULTS: VAS changes were -9.3 for rest pain, -24.0 for walking pain, and -15.0 for night pain (all p < 0.05). Walking VAS decreased by at least 30% in 65.7% and by at least 50% in 42.9% of knees. Four KOOS subscales improved, including KOOS Pain by 12.8 points (p < 0.001). No significant group-level changes were observed in KL grade, alignment, or BML scores. Hoffa-synovitis and effusion-synovitis scores decreased. No serious procedure-related adverse events were documented. CONCLUSION: CRFA was associated with improved pain and function at 3 months without group-level worsening in KL grade, alignment, or BML scores. Longer-term controlled studies are required.

  2. Review Reg Anesth Pain MedPublished 5 Oct 2026 Ferreira-Silva N et al.
    Navigating current controversies in radiofrequency ablation of the genicular nerves for chronic knee pain in osteoarthritis: a daring discourse.
    AI summary of the abstract, unverified
    • This is a narrative discourse rather than a trial, reviewing debates on radiofrequency ablation of the genicular nerves for chronic knee osteoarthritis pain.
    • It addresses six controversies: prognostic blocks, final cannula placement, which nerves to target, ultrasound versus fluoroscopy, pulsed radiofrequency, and use after knee arthroplasty.
    • The abstract notes earlier studies reporting pain relief lasting up to 12 months, while recent randomized trials have questioned RFA efficacy.
    • The authors attribute conflicting results partly to heterogeneity in patient selection and technical protocols, and aim to guide clinicians and prompt further research.
    Original abstract (PubMed)

    Chronic knee joint pain affects millions worldwide, with radiofrequency ablation (RFA) of genicular nerves emerging as a potential treatment in the last 15 years. Despite its growing popularity, with studies demonstrating its efficacy in pain reduction for up to 12 months, recent randomized controlled trials have questioned the efficacy of RFA. Discrepancies in study results may partially be explained by the heterogeneity of patient selection and technical protocols.This daring discourse aims to explore and critically analyze the ongoing debates surrounding RFA of the genicular nerves, addressing key controversies, namely: (1) Is there a role for performing prognostic blocks prior to RFA?; (2) What are the optimal target sites for final cannulae placement for the classical targets?; (3) Which and how many nerves should be targeted in RFA procedures?; (4) What are the comparative benefits of using ultrasound versus fluoroscopy guidance, and whether a combined technique may be advantageous?; (5) Is there a potential role for pulsed radiofrequency of the genicular nerves?; (6) Should genicular nerve RFA be performed after total knee arthroplasty?Through this in-depth discussion, we aim to guide pain medicine clinicians in informed decision-making and encourage further research in this field.

  3. Other Pain MedPublished 28 Sep 2026 Fodjeu G et al.
    Mapping Genicular Nerve Endings for Optimal Pain Management: A Comparative Cadaveric Analysis Between Native Versus Prosthetic Knee.
    AI summary of the abstract, unverified
    • Cadaveric study of ten native and ten prosthetic knee capsules, sampling five genicular nerve target regions with histologic and immunohistochemical analysis.
    • Compared intracapsular nerve ending and vascular densities between native and prosthetic knees; no clinical treatment was tested.
    • Native knees had higher free nerve ending density (p < 0.001), while prosthetic knees had greater vascular density (p = 0.001) and more Pacini, Golgi and unclassified endings.
    • FNE-vascular correlation was modest in native knees (r = 0.41) and negligible in prosthetic knees (r = 0.09); the authors suggest dense FNEs support nerve-targeted OA pain treatment.
    Original abstract (PubMed)

    BACKGROUND: Chronic knee pain, often due to osteoarthritis (OA), is frequently treated with genicular nerve blocks, radiofrequency ablation (RFA) or genicular artery embolization (GAE). However, the intracapsular distribution of nerve endings and vascular networks key pain parameters remains poorly defined in native and prosthetic knees. QUESTIONS/PURPOSES: We compared the distribution of intracapsular nerve endings and vascular density in native versus prosthetic knee capsules across five genicular nerve targets in relation to knee pain. METHODS: Ten native and ten prosthetic cadaveric knees were analyzed. Capsular samples (20 × 5 mm) were harvested from regions innervated by the superior medial, superior lateral, and inferior genicular nerves, the recurrent fibular nerve, and the infrapatellar branch of the saphenous nerve. Nerve endings and vascular densities were quantified after histologic and immunohistochemical analysis comparatively. RESULTS: Native knees had higher free nerve ending (FNE) density (p < 0.001), while prosthetic knees showed greater vascular density (p = 0.001) and increased Pacini (p = 0.006), Golgi (p = 0.01), and unclassified endings (p = 0.019). Correlation between FNE and vascular density was modest in native knees (r = 0.41) and negligible in prosthetic knees (r = 0.09). Patterns were consistent across all nerve targets. All five nerve targets showed no difference in their mechanoreceptor and vascular density distribution. CONCLUSION: Dense FNE populations in native knees support genicular nerve-targeted interventions for OA pain. The increased vascularity and mechanoreceptor innervation identified in prosthetic knees suggest that inflammatory, angiogenic, and sensory mechanisms may contribute to persistent post-surgical pain. Whether interventions targeting these pathways, such as radiofrequency ablation or genicular artery embolization, provide better clinical benefit together remains to be established.

  4. Review CureusPublished 23 Sep 2026 Zuccarini F et al.
    One Size Does Not Fit All: A Systematic Review of Preoperative Genicular Nerve Radiofrequency Ablation in Total Knee Arthroplasty.
    AI summary of the abstract, unverified
    • This systematic review pooled prospective randomized trials and observational studies of preoperative genicular nerve radiofrequency ablation before total knee arthroplasty.
    • The comparison was ablation against control procedures, assessing function, pain, opioid use, length of stay, and complications.
    • Trials showed no meaningful improvement in medium- to long-term function, acute pain, or length of stay, and no clear rise in complications was found.
    • Retrospective data hinted at fewer long-term opioid refills, but no study stratified outcomes by baseline risk, so high-risk patients remain untested.
    Original abstract (PubMed)

    Persistent postsurgical pain and poor functional recovery remain significant challenges following total knee arthroplasty, with patients presenting with severe preoperative pain, central sensitization, or psychological comorbidities at elevated risk. Preoperative genicular nerve radiofrequency ablation aims to preemptively block nociceptive signaling via thermal neuro-destruction or sensory neuromodulation, but its clinical utility remains debated. This systematic review evaluates whether ablation improves functional outcomes, pain trajectories, and opioid consumption after primary joint replacement, focusing on vulnerable populations. Following established reporting guidelines, major biomedical databases were comprehensively searched to identify prospective randomized trials and observational studies evaluating functional scores, pain intensity, opioid consumption, length of stay, and complication rates. No clear increase in reported complications was identified in the available studies, although the evidence base is insufficient to exclude uncommon adverse events. Trial evidence showed no statistically or clinically meaningful improvements in medium- to long-term functional scores, acute postoperative pain, or length of stay compared to control procedures. While retrospective database data suggested a potential reduction in long-term opioid refills, none of the available literature stratified outcomes based on baseline patient risk profiles. Preoperative genicular nerve radiofrequency ablation is safe, but current evidence does not support its routine, unselected application in general surgical populations. Its true clinical value remains untested in high-risk individuals predisposed to chronic postsurgical pain, highlighting a clear need for targeted, risk-stratified trials.

  5. Other J Pain ResPublished 19 Sep 2026 Matsuoka Y
    Clinical Outcomes and Repeat-CRFA-Free Survival After Ultrasound-Guided Cooled Radiofrequency Ablation Using the Matsuoka Direct Nerve Targeting (MDNT) Technique for Knee Osteoarthritis: A Retrospective Cohort Study of 1,025 Consecutive Knees.
    AI summary of the abstract, unverified
    • Retrospective single-center cohort of 1,025 consecutive knees with symptomatic knee osteoarthritis treated between June 2024 and June 2026.
    • All knees received ultrasound-guided cooled radiofrequency ablation using the MDNT technique, which adds physiological confirmation before ablation; there was no comparator group.
    • Mean NRS pain fell from 7.76 to 2.46 by postoperative day 1 (mean reduction 5.29; 95% CI 5.16-5.43; P < 0.001) among 1,021 knees with early data.
    • Repeat CRFA occurred in 8 of 1,025 knees (0.8%), and repeat-CRFA-free survival was 99.8% at 12 months; the authors call the findings hypothesis-generating.
    Original abstract (PubMed)

    BACKGROUND: Cooled radiofrequency ablation (CRFA) is a minimally invasive treatment for knee osteoarthritis (KOA) pain. Conventional techniques commonly use anatomical landmarks to estimate genicular nerve location. The Matsuoka Direct Nerve Targeting (MDNT) Technique combines ultrasound visualization with physiological confirmation before ablation. We evaluated clinical outcomes and repeat-CRFA-free survival after CRFA using this technique. METHODS: This retrospective single-center cohort included 1,025 consecutive knees with symptomatic KOA treated between June 2024 and June 2026. NRS pain scores were recorded preoperatively, on postoperative day 1, and at approximately 1 year when available through rolling telephone follow-up. Repeat CRFA, complications, and conversion to total knee arthroplasty were secondary outcomes. Repeat-CRFA-free survival was estimated using Kaplan-Meier analysis. RESULTS: Among 1,021 knees with complete early NRS data, mean NRS decreased from 7.76 ± 1.31 preoperatively to 2.46 ± 1.93 on postoperative day 1 (mean reduction, 5.29; 95% CI, 5.16-5.43; P < 0.001). One-year NRS data were available for 246 knees, in which mean NRS decreased from 8.15 ± 1.12 preoperatively to 2.29 ± 2.06 at approximately 1 year. Repeat CRFA was performed in 8 of 1,025 knees (0.8%; 95% CI, 0.4-1.5%), and TKA was reported as planned in 1 knee (0.1%). Kaplan-Meier repeat-CRFA-free survival was 99.8% at 12 months and 96.9% at 20 months. No major procedure-related complications were observed. CONCLUSION: Ultrasound-guided CRFA using MDNT was associated with substantial early pain reduction, sustained pain relief among knees with available one-year follow-up, a low observed repeat-CRFA rate, and a favorable safety profile. Because this was a retrospective single-center, single-operator study without a comparator, the findings are hypothesis-generating and do not establish superiority over established techniques. Prospective multicenter comparative studies are warranted.

  6. Other CureusPublished 18 Sep 2026 Chen M et al.
    Patient-Reported Outcomes Following Two-Tined Three-Site Conventional Radiofrequency Ablation of Genicular Nerves for Chronic Knee Pain.
    AI summary of the abstract, unverified
    • A retrospective chart review of 31 patients who received 38 conventional genicular nerve RFAs at an academic medical center from 2016 to 2023.
    • Conventional radiofrequency ablation of three genicular nerves using two-tined electrodes, in patients with a prior positive genicular nerve block; no comparator group was reported.
    • Mean NRS reduction was -3.17 at 0-3 months, -1.31 at 3-6 months, and -1.92 at 6-12 months, and half of patients kept an MCID-level reduction for 11.17 months (95% CI: 7.29, 13.40).
    • PROMIS Physical Health, PROMIS Mental Health, and PHQ-9 showed no statistically significant change, and a history of depression was associated with treatment failure.
    Original abstract (PubMed)

    BACKGROUND: Genicular nerve radiofrequency ablation (GNRFA) has emerged as an effective therapy for chronic knee pain. Although some studies have evaluated its effectiveness, there is limited real-world data on the long-term patient-reported outcome (PRO) data for GNRFAs. OBJECTIVE: This study aimed to evaluate PROs following conventional GNRFAs performed using two-tined electrodes and the classical three-site technique targeting the superior medial, superior lateral, and inferior medial genicular nerves. METHODS: We performed a retrospective chart review to gather data from consecutive GNRFAs at an academic medical center from 2016 to 2023. Inclusion criteria were all adult patients who received a conventional GNRFA performed using the classical three-site technique using two-tined electrodes. All included subjects were confirmed to have a positive diagnostic response (≥50% Numeric Rating Scale (NRS) reduction) to a previous genicular nerve block. Primary outcomes were NRS pain scores, Patient Reported Outcomes Measurement Information System (PROMIS) Global Health, and Patient Health Questionnaire-9 (PHQ-9). RESULTS: A total of 31 patients underwent 38 GNRFAs. Relative to the pre-procedure baseline, the average NRS reduction post-procedurally was -3.17 during 0-3 months (p<0.0001), -1.31 during 3-6 months (p<0.05), and -1.92 during 6-12 months (p<0.05). Half of all patients maintained pain relief (NRS reduction greater than or equal to a minimal clinically important difference (MCID) of -2.0) for 11.17 months (95% CI: 7.29, 13.40). Although there was a positive trend for improvement in the quality-of-life measures, no statistically significant post-procedure improvement or worsening was observed during all time periods for PROMIS Physical Health, PROMIS Mental Health, and PHQ-9. Lastly, a history of depression was associated with treatment failure. CONCLUSION: In this real-world cohort, conventional GNRFA using the classical three-site technique demonstrated robust short-term pain reduction, and at least half of the cohort maintained clinically meaningful pain improvements for 11 months. For chronic knee pain, GNRFA is a reasonable therapeutic option in appropriately selected patients.

  7. Observational Med Sci MonitPublished 17 Sep 2026 Moria HA
    Long-Term Pain and Functional Outcomes After Cooled Genicular Radiofrequency Ablation With or Without Adjunctive Intra-Articular Botulinum Toxin Type A in Knee Osteoarthritis.
    AI summary of the abstract, unverified
    • Retrospective observational comparative-effectiveness cohort of 90 patients with moderate-to-severe knee osteoarthritis, followed for 24 months.
    • Compared cooled genicular radiofrequency ablation alone (n=50) with the same ablation plus intra-articular botulinum toxin type A (n=40), with a planned repeat BoNT-A injection at about 12 months in the combination group.
    • Significant treatment-by-time interactions were found for NRS (ß=-0.84, 95% CI -1.21 to -0.47; P=0.0002) and WOMAC (ß=-6.3, 95% CI -9.4 to -3.2; P=0.0003).
    • At 24 months, responder rates were 86.5% with combination therapy versus 51.1% with ablation alone (P=0.0004); the authors call for randomized trials to confirm this.
    Original abstract (PubMed)

    BACKGROUND Cooled genicular radiofrequency ablation (CRFA) is used to treat symptomatic knee osteoarthritis (OA), although treatment response may decline over time. This study evaluated 24-month outcomes of CRFA alone versus CRFA combined with intra-articular botulinum toxin type A (BoNT-A). MATERIAL AND METHODS In this retrospective observational comparative-effectiveness cohort study, 90 patients with moderate-to-severe knee OA underwent CRFA alone (n = 50) or CRFA plus intra-articular BoNT-A (n=40). The combination group received BoNT-A at baseline and a planned repeat injection at ~12 months. Pain and function were assessed using the Numerical Rating Scale (NRS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The primary durability endpoint was the between-group difference in longitudinal NRS trajectories over 24 months, assessed using adjusted mixed-effects modeling. RESULTS Both groups demonstrated substantial early improvement; outcome trajectories diverged after ~12 months. Significant treatment-by-time interactions were observed for NRS (ß=-0.84, 95% confidence interval [CI] -1.21 to -0.47; P=0.0002) and WOMAC outcomes (ß=-6.3, 95% CI -9.4 to -3.2; P=0.0003). At 24 months, mean observed NRS scores were 4.2±2.3 after CRFA alone and 1.8±0.9 after CRFA plus BoNT-A; responder rates were 51.1% and 86.5%, respectively (P=0.0004). CONCLUSIONS In this retrospective observational cohort, a longitudinal treatment pathway combining CRFA with intra-articular BoNT-A was associated with more sustained pain relief and functional improvement over 24 months than CRFA alone. Prospective randomized studies are needed to confirm these findings and clarify the independent contributions of adjunctive and repeat intra-articular BoNT-A.

  8. Review Skeletal RadiolPublished 15 Sep 2026 Gonzalez FM et al.
    Local anesthetic selection for spine and large joint radiofrequency ablation: a practical review for the musculoskeletal radiologist.
    AI summary of the abstract, unverified
    • This narrative practical review synthesizes indirect pharmacological and adjacent procedural evidence, with no dedicated comparative trial of local anesthetics within RFA.
    • It suggests lidocaine 1% as a default for skin and track anesthesia, and avoiding lidocaine 2% near the target nerve where stimulation testing is done, based on mechanistic reasoning.
    • Across five randomized trials outside interventional pain settings, premixing lidocaine and bupivacaine showed no onset advantage over bupivacaine alone and sometimes shortened duration.
    • The authors conclude these considerations are provisional and call for prospective studies, and they provide an allergy substitution pathway centered on formal allergist evaluation.
    Original abstract (PubMed)

    Local anesthetic (LA) selection for radiofrequency ablation (RFA) of spinal medial branch nerves, sacroiliac joint lateral branches, and large peripheral joint articular branches has not been addressed by any dedicated document. The concentration, class, and sequencing of agents used during needle placement, stimulation testing, and pre-lesioning injection have plausible implications for procedural accuracy and post-procedural analgesia. This review synthesizes pharmacological data and adjacent procedural literature into practice considerations for the musculoskeletal radiologist. No randomized or prospective comparative trial has evaluated LA agents, concentrations, or sequencing within an RFA procedure; every statement therefore rests on indirect evidence, mechanistic reasoning, or the authors' practice, and each is labeled accordingly. Lidocaine 1% is a reasonable default for skin, subcutaneous, and deep track anesthesia. Where sensory and/or motor stimulation testing is performed, there is a mechanistic argument for avoiding lidocaine 2% close to the target nerve, since selectivity between fiber classes falls as concentration rises; that argument derives from epidural quantitative sensory testing and rodent electrophysiology, has not been tested in RFA, and no study has shown that lidocaine 2% impairs stimulation testing or procedural outcome. Bupivacaine 0.25% or ropivacaine 0.2% is a reasonable choice for perineural injection before lesioning. Premixing lidocaine and bupivacaine has no demonstrated advantage: across five randomized trials, all outside interventional pain settings and heterogeneous in design, mixtures did not accelerate onset relative to bupivacaine alone and in several curtailed its duration; two also found same-site sequential injection no better than premixing. Ropivacaine is a reasonable preference in cardiac conduction disease or multi-level procedures. A structured allergy substitution pathway is provided with formal allergist evaluation as the central step. These considerations are offered to inform practice and to prompt the prospective studies the field lacks.

  9. Other Pain PhysicianPublished Sep 2026 (day not reported) Soin A et al.
    Local Coverage Determinations for Peripheral Nerve Injections and Procedures for Chronic Pain: Policy Changes, Clinical Limitations, and Health-Equity Implications.
    AI summary of the abstract, unverified
    • This health-policy analysis compares September 2025 draft Medicare LCDs for peripheral nerve injections in chronic pain with the final policies, and examines their equity implications.
    • The draft policies would have limited coverage mainly to trigeminal neuralgia radiofrequency and certain corticosteroid injections, with lifetime caps; the final policies restored criteria-based coverage for several blocks.
    • Four contractors published materially identical final LCDs, effective October 25, 2026, while participation in the collaborative process was reported separately from final publication.
    • Pudendal, intercostal, ganglion impar, ulnar, and other peripheral-nerve procedures remain noncovered for chronic pain, and the authors highlight access implications of geographically discordant coverage.
    Original abstract (PubMed)

    Five Medicare Administrative Contractors (MACs)-CGS, Palmetto GBA, Wellpoint Federal (formerly National Government Services), Wisconsin Physicians Service, and Noridian-participated in a collaborative policy-development process addressing peripheral nerve injections and related procedures for chronic pain. Novitas Solutions and First Coast Service Options did not participate. The September 2025 draft policies would have limited coverage principally to radiofrequency neurolysis for trigeminal neuralgia and corticosteroid injections for carpal tunnel syndrome and Morton neuroma, with lifetime caps on the latter procedures. After public comment and further evidence review, four contractors published materially identical final LCDs, with a notice period from September 10 through October 24, 2026, and an effective date of October 25, 2026. The final policies restored limited, criteria-based coverage for sympathetic blocks in complex regional pain syndrome, genicular nerve blocks and ablation for selected patients with knee osteoarthritis, greater occipital nerve blocks for occipital neuralgia, and selected suprascapular nerve blocks. They also removed the lifetime caps on median-nerve and Morton-neuroma injections. Pudendal, intercostal, ganglion impar, ulnar, and unspecified other peripheral-nerve procedures remain noncovered when performed for chronic pain. This health-policy analysis compares the draft and final policies, distinguishes Noridian's participation in the collaborative process from publication of a final LCD, summarizes coding and documentation requirements, and examines the access and health-equity implications of geographically discordant Medicare coverage.

  10. Other Turk J Phys Med RehabilPublished 1 Sep 2026 Bilim S et al.
    The effects of genicular nerves radiofrequency ablation treatment on postural stability in patients with knee osteoarthritis.
    AI summary of the abstract, unverified
    • Pre-post study of 22 patients with knee osteoarthritis, assessed before treatment, at 3 weeks, and at 3 months.
    • Patients received genicular nerve radiofrequency ablation, and the abstract describes no separate control group.
    • Lift-up index and movement time improved significantly in both legs at 3 weeks and 3 months, while pain fell from 8.09 to 2.41 at 3 weeks and 4.18 at 3 months (p<0.0001).
    • The authors conclude GNRFA contributes positively to postural stability; WOMAC function also improved, from 58.69 to 23.05 at 3 weeks and 36.15 at 3 months (p<0.001).
    Original abstract (PubMed)

    OBJECTIVES: This study aimed to investigate the effects of genicular nerves radiofrequency ablation (GNRFA) treatment on postural stability in patients with knee osteoarthritis. PATIENTS AND METHODS: Twenty-two patients were included in the study. Postural stability was assessed using the walk across test, sit-to-stand test, step-up and over test and modified clinical test of balance in sensory interaction tests with the NeuroCom Balance Master device. A numeric rating scale and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) criterion was used to determine changes pain levels and the functionality. Three evaluations were performed before treatment, 3 weeks and 3 months after treatment. RESULTS: After GNRFA, changes in patients' postural stability parameters showed that the lift-up index and the movement time improved significantly in both lower extremities 3 weeks and 3 months. There was a significant reduction in pain levels [8.09±1.01 to 2.41±1.73 in the 3rd week and to 4.18±1.79 in the 3rd month (p<0.0001 for both)]. A significant improvement in WOMAC functionality scores was seen; they started with a mean of 58.69±11.25 at baseline and changed to 23.05±12.08 at the 3rd week and 36.15±16.45 at the 3rd month (p<0.001 for both). CONCLUSION: After GNRFA treatment, the lift-up index and the movement time, which are the dynamic postural stability parameters has improved significantly. These results show that GNRFA treatment contributes positively to postural stability.

  11. Other North Clin IstanbPublished 28 Aug 2026 Gozukizil ST et al.
    Long-term efficacy of genicular nerve radiofrequency ablation in patients with advanced knee osteoarthritis: A retrospective cohort study.
    AI summary of the abstract, unverified
    • Retrospective cohort of 44 patients with advanced knee osteoarthritis and chronic knee pain unresponsive to at least 3 months of conservative care.
    • Ultrasound-guided radiofrequency ablation of three genicular nerves, with NRS and WOMAC scores assessed at baseline and at 1, 6, and 12 months; no comparator group was reported.
    • NRS and WOMAC scores fell significantly at all follow-ups (p<0.001); clinical success (≥50% pain reduction) was 81.8% at 1 month, 75.0% at 6 months, and 11.4% at 12 months.
    • Authors conclude benefit was greatest within 6 months, suggesting GNRFA is a medium-term option rather than a permanent one; no serious adverse events were reported.
    Original abstract (PubMed)

    OBJECTIVE: Conventional treatments for advanced knee osteoarthritis (OA) are often insufficient, and surgery is not always feasible. This retrospective cohort study aimed to evaluate changes in pain, function, and safety over 12 months following ultrasound-guided genicular nerve radiofrequency ablation (GNRFA). METHODS: We included 44 patients with chronic knee pain unresponsive to conservative treatments for at least 3 months. All patients underwent US-guided radiofrequency ablation of the superomedial, superolateral, and inferomedial genicular nerves. Pain numeric rating scale (NRS) and functional status Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were assessed at baseline, and routinely at 1, 6, and 12 months post-procedure. RESULTS: Compared to baseline, mean NRS and WOMAC scores decreased significantly at all follow-up points (p<0.001). Based on a ≥50% pain reduction threshold (clinical success), 81.8% of patients achieved success at 1 month, and 75.0% maintained it at 6 months. By 12 months, this rate declined to 11.4%. No statistically significant differences in outcomes were observed between radiological grades. A strong positive correlation between NRS and WOMAC scores was observed across all follow-up times. No serious adverse events were reported. CONCLUSION: US-guided GNRFA was associated with improvements in pain and function, which were most pronounced within the first 6 months in patients with advanced knee OA. However, the marked decline in responder rates at 12 months suggests reduced durability beyond 6 months. These findings suggest that GNRFA may serve as a medium-term management option rather than a permanent solution, and that re-evaluation may be appropriate in patients with recurrent symptoms.

  12. Other Asia Pac J Sports Med Arthrosc Rehabil TechnolPublished 24 Aug 2026 Tsubosaka M et al.
    Cooled radiofrequency ablation for patients with chronic postsurgical pain after total knee arthroplasty: Pilot clinical trial.
    AI summary of the abstract, unverified
    • Prospective single-arm pilot trial in consecutive patients with chronic postsurgical pain after total knee arthroplasty; 5 of 15 screened patients completed the study.
    • Patients received cooled radiofrequency ablation (Coolief system), with change in NRS pain score from baseline to 6 months as the primary endpoint.
    • The NRS change did not reach statistical significance at 6 months, though responder analysis showed a substantial proportion with clinically meaningful improvement; the KSS trend was also nonsignificant.
    • No adverse events were reported, and the authors conclude the approach appears safe and potentially effective, with larger studies needed.
    Original abstract (PubMed)

    INTRODUCTION: Total knee arthroplasty (TKA) generally provides substantial and durable relief in end-stage knee osteoarthritis, yet a proportion of patients develops chronic postsurgical pain (CPSP). Conventional analgesics often fail to adequately address this condition. Cooled radiofrequency ablation (CRFA) has shown effectiveness in knee osteoarthritis, but its utility for patients with CPSP after TKA has not been investigated. This study aimed to report a phase I/IIa clinical trial regarding CRFA for patients with CPSP after TKA. MATERIALS AND METHODS: This prospective pilot study (jRCTs052230123) enrolled consecutive patients with CPSP between November 2023 and August 2025. Inclusion criteria included persistent pain ≥6 months after TKA, inadequate response to standard analgesics (NRS ≥5), and ≥50% pain reduction after diagnostic genicular nerve block. Following informed consent, participants underwent CRFA using the Coolief® system. The primary endpoint was the change in Numeric Rating Scale (NRS) pain score from baseline to 6 months. 2011 Knee Society Score (KSS) was also used for the efficacy evaluation. As for the safety evaluation, the occurrence and outcomes of any severe adverse events between the day of treatment and 6 months post-treatment were recorded. RESULTS: Of 15 screened patients, 5 met all criteria and completed the study. CRFA resulted in a consistent reduction in pain intensity; however, the change in NRS scores did not reach statistical significance at 6 months. Responder analyses demonstrated that a substantial proportion of patients achieved clinically meaningful improvements at 6 months. Although the 2011 KSS showed a trend toward improvement, the change was not statistically significant. No adverse events or complications occurred. CONCLUSIONS: CRFA provided clinically meaningful pain relief without adverse events in patients with CPSP after TKA. These findings suggest that CRFA is a safe and potentially effective therapeutic option. Larger studies are needed to verify its clinical value.

  13. RCT Pain MedPublished 20 Aug 2026 Ertilav D et al.
    Comparison of the Effects of Phenol Neurolysis and Conventional Radiofrequency Thermocoagulation Applied to the Genicular Nerves on Pain in Patients Who Underwent Knee Arthroplasty: A Prospective, Controlled Study.
    AI summary of the abstract, unverified
    • Prospective quasi-randomized controlled trial of 109 patients with persistent pain after knee arthroplasty, assigned by procedure group to genicular nerve treatment.
    • Compared conventional radiofrequency thermocoagulation (RFT) with chemical neurolysis using phenol of the genicular nerves.
    • Phenol had lower NRS at 1 month (3.67 vs 4.09, p=0.015) and 6 months (5.02 vs 6.52, p<0.001); 6-month ≥50% improvement was 43.6% vs 18.5% (p=0.005).
    • Authors conclude both treatments are effective for persistent post-arthroplasty pain, complications were similar (5.5% vs 3.7%), and phenol's short-term benefit needs long-term confirmation.
    Original abstract (PubMed)

    OBJECTIVE: This study aimed to compare conventional radiofrequency thermocoagulation (RFT) with chemical neurolysis in patients who underwent knee arthroplasty and continued to experience pain. MATERIALS AND METHODS: This was a prospective, quasi-randomized controlled trial. A total of 109 patients who underwent knee arthroplasty were evaluated and assigned to two groups according to the interventional procedures applied to the genicular nerves: Group 1 included patients who underwent conventional RFT, and Group 2 included patients who underwent chemical neurolysis of the genicular nerves using phenol. The Numeric Rating Scale (NRS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were used to assess pain intensity before the procedure and at 1, 3, and 6-month follow-ups. RESULTS: The demographic and clinical characteristics were similar between the conventional RFT and phenol groups. At one month, the mean NRS was 4.09±0.73 in the RFT group and 3.67±0.73 in the phenol group, significantly lower in the phenol group (p = 0.015)[d = 0.503; 95% CI]. The mean NRS scores were 5.57±0.81 and 4.64±0.75, respectively, at the third month (p < 0.001)[d:1.195 95%CI], and 6.52±1.38 and 5.02±1.46 at the sixth month (p < 0.001)[d:1.055 95%CI]. At three months, the NRS ≥50% improvement rate was 29.6% in the RFT group and 49.1% in the phenol group, with a significant difference in favor of the phenol group (p = 0.038)[OR:2.290 95% CI]. At six months, the NRS ≥50% improvement rate was 18.5% and 43.6%, respectively, and the difference was statistically significant in favor of the phenol group (p = 0.005)[OR:3.406 95% CI]. NRS≥30% improvement rate was similar at 1 month, at 98.1% in the RFT group and 98.2% in the phenol group (p = 1.000)[OR: 1.019 95% CI]. At three months, these rates were 83.3% and 90.9%, respectively, with no statistically significant difference (p = 0.237)[OR: 2.000 95% CI]. At six months, NRS ≥30% improvement was observed in 72.2% of the RFT group and 87.3% of the phenol group, with a borderline statistically significant difference (p = 0.050)[OR: 2.637 95% CI]. The complication rate was 3.7% in the RFT group and 5.5% in the phenol group, with no significant difference between the two groups (p = 1.000) [OR: 1.500 95% CI]. CONCLUSION: Phenol neurolysis and conventional RFT of the genicular nerves are effective treatments for patients with persistent pain after knee arthroplasty. The results demonstrating the short-term efficacy of phenol neurolysis in patients undergoing arthroplasty should be supported by long-term follow-up studies.

  14. Review Ann R Coll Surg EnglPublished 19 Aug 2026 Onobun D et al.
    Comparative outcomes of genicular nerve block and radiofrequency ablation in knee osteoarthritis.
    AI summary of the abstract, unverified
    • This PRISMA systematic review pooled 19 studies, including sham-controlled trials, active-comparator trials and cohorts, of genicular nerve block and radiofrequency ablation for knee osteoarthritis.
    • Pooled random-effects meta-analysis was used where data were homogeneous, and structured narrative synthesis otherwise.
    • RFA was associated with larger and more durable pain relief than GNB, often lasting 6-12 months, though most of the comparison evidence is indirect.
    • Both approaches reduced pain with no serious procedure-related adverse events reported, and the authors call for head-to-head trials with standardised protocols and longer follow-up.
    Original abstract (PubMed)

    INTRODUCTION: Genicular nerve block (GNB) and radiofrequency ablation (RFA) are increasingly utilised for pain management in knee osteoarthritis, yet their comparative effectiveness, durability and clinical role remain uncertain. This systematic review aimed to compare outcomes of GNB and RFA in patients with knee osteoarthritis. METHODS: A systematic review was conducted in accordance with PRISMA guidance. MEDLINE, Embase, CENTRAL, CINAHL and Web of Science were searched for randomised controlled trials and comparative observational studies evaluating GNB and/or RFA for knee osteoarthritis. Outcomes included pain, function, durability of effect, safety and reported progression to total knee replacement (TKR). Random-effects meta-analysis was performed where data were sufficiently homogeneous; otherwise, structured narrative synthesis was undertaken. FINDINGS: Nineteen studies were included, comprising sham-controlled trials, active-comparator trials and prospective or retrospective cohorts. Both GNB and RFA were associated with reductions in pain compared with comparators. Across studies, RFA demonstrated larger and more durable pain relief than GNB, with benefits commonly sustained for 6-12 months and, in some cohorts, beyond 1 year. Functional improvements were variable but were most consistently observed following RFA using broader genicular nerve targeting strategies. No serious procedure-related adverse events were reported, and minor complications were infrequent and self-limiting. Reported conversion to TKR during study follow-up was rare, though follow-up duration and study design limited causal inference. CONCLUSIONS: Genicular nerve interventions provide clinically meaningful pain relief with favourable safety profiles in knee osteoarthritis. Across the available studies, RFA was associated with larger and more durable improvements in pain than GNB, although most evidence derives from indirect comparisons rather than direct head-to-head trials. Further high-quality studies with standardised protocols and longer follow-up are required to clarify long-term outcomes and surgical implications.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

Recruiting, est. 2026-08-31
Active not recruiting, est. 2026-12
Not yet recruiting, est. 2026-12-01
Not yet recruiting, est. 2027-03-30
Not yet recruiting, est. 2027-04-30
Recruiting, est. 2027-06-01
Radiofrequency in Knee Osteoarthritis
NCT07700784, target n=50
Not yet recruiting, est. 2027-08
Recruiting, est. 2027-08-20
Recruiting, est. 2028-07-14
Not yet recruiting, est. 2028-08-20
Not yet recruiting, est. 2028-10